Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland

Abstract

Treatment intensity was not sufficient to maintain the initial improvement in visual acuity by ranibizumab treatment. Real-life results for visual acuity and injection frequency in the German cohort were worse at that time than in other countries. Regular follow-up visits as well as timely retreatment in the presence of signs of disease activity are required to achieve optimal results in wAMD when applying a pro re nata-based strategy.

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results

“…The long-term follow-up results of this study demonstrate that although the average BCVA decreased by 13 letters compared with the BCVA at baseline after 5-year treatment with ranibizumab, 37.8% of the patients had improved vision and 13.5% among whom gain 15 letters or more, indicating that the long-term efficacy of ranibizumab to treat wAMD in Chinese people is clear and definite. Our results are similar to the other researches [10, 11]. We found that the average BCVA in the first, second, and third years had no significant difference compared with that at baseline, indicating that most of the patients can maintain their visual function in the first three years, results which are similar to other reports [12].…”

A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal

“…However, a number of alternative regimens, including as-needed dosing, have also been proposed and are widely used in clinical practice. [4][5][6][7][8] Results from clinical studies indicate that outcomes are more variable with lessfrequent intravitreal ranibizumab dosing. [9][10][11] LUMIERE, a retrospective observational study of 551 patients with wAMD, showed that poor compliance with intravitreal ranibizumab was associated with loss of initial treatment gains over a 12 -month period, from 5.3 letters at month three to 3.2 letters at month 12.…”

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“

“…In den letzten 5 Jahren hat sich darüber hinaus die Bewertung der intravitrealen Therapie deutlich verändert. So zeigen "real-life"-Daten der ersten intravitrealen Behandlungsjahre, dass die meisten Patienten zu wenig intensiv und mit meist weniger als 5 Spritzen pro Jahr behandelt wurden [10]. Heute wissen wir, dass dies eine Unterbehandlung der AMD darstellt und deshalb die Behandlungsresultate oft insuffizient bleiben.…”